...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Urology >Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer
【24h】

Clinical outcome of surgical management for symptomatic metastatic spinal cord compression from prostate cancer

机译：前列腺癌症症状转移性脊髓压缩外科手术管理的临床结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Metastatic spinal cord compression (MSCC) from prostate cancer (PC) influences not only patients’ prognosis but also their quality of life. However, little is known about the clinical outcome of surgery for MSCC from PC. We evaluated both the oncological and functional outcomes of decompression and reconstruction surgery for patients with symptomatic MSCC from PC. We assessed 19 patients who underwent decompression and reconstruction surgery for symptomatic MSCC from PC. Of these 19 patients, 8 had metastatic hormone-na?ve PC (mHNPC) and 11 had metastatic castration-resistant PC (mCRPC). The median age of the patients with mHNPC and mCRPC was 72 and 65?years, respectively. The median prostate-specific antigen level at the time of diagnosis of MSCC in patients with mHNPC and mCRPC was 910 and 67?ng/mL, respectively. Although two of eight patients (25.0%) with mHNPC were ambulatory preoperatively, six patients (75.0%) were ambulatory postoperatively. Among 11 patients with mCRPC, only 3 (27.3%) were ambulatory preoperatively, while 6 (54.5%) were ambulatory postoperatively. The median postoperative overall survival among patients with mHNPC and mCRPC were not reached and 8?months, respectively. Decompression and reconstruction surgery for symptomatic MSCC from PC might contribute to a favorable functional outcome among men with mHNPC and mCRPC. However, its role in improving the oncological outcome remains unclear. The treatment strategy should be chosen by shared decision-making among patients, urologists, radiation oncologists, and orthopedic surgeons.
机译：来自前列腺癌（PC）的转移性脊髓压缩（MSCC）不仅影响患者的预后，还影响它们的生活质量。但是，关于来自PC的MSCC的手术的临床结果几乎是知名的。我们评估了PC症状MSCC患者的减压和重建手术的肿瘤和功能性结果。我们评估了来自PC的症状MSCC的减压和重建手术的19名患者。在这19名患者中，8例具有转移性激素-NA'VE PC（MHNPC）和11具有转移性阉割耐药性PC（MCRPC）。 MHNPC和MCRPC患者的中位年龄分别为72和65岁。在MHNPC和MCRPC患者诊断MSCC时的中位前列腺特异性抗原水平分别为910和67Ω·Ng / mL。虽然八名患者中的两个患者（25.0％）术前术前，术后6名患者（75.0％）术后术后。在11名患有MCRPC患者中，术前只有3（27.3％），而6（54.5％）术后的动态。患有MHNPC和MCRPC患者的中位术后总生存率分别达到8月8日。来自PC的症状MSCC的减压和重建手术可能有助于MHNPC和MCRPC的男性有利的功能结果。然而，它在改善肿瘤结果方面的作用仍然不清楚。应由患者，泌尿科医生，辐射诱发学家和矫形外科医生共享决策选择治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号